RxDoctor Payments Data

Derrick Birmingham

Physician Assistant · Bronx, NYNPI 1952336380

Payments from drug & device makers

$1,705in general payments, 2019–2025

Across 100 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$539
  • Merck$184
  • Boehringer Ingelheim$152
  • Lilly USA, LLC$123
  • Viiv Healthcare Company$101
  • AstraZeneca$83
  • plus $523 from 12 others

What the payments were for

  • Food & beverage$1,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,705 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$4,712
Medicare patients
14
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$108,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$55,071
JardianceEmpagliflozin46$47,445
JanuviaSitagliptin Phosphate61$44,572
TrulicityDulaglutide39$42,482
TivicayDolutegravir Sodium17$33,019
DescovyEmtricitabine/Tenofov Alafenam16$30,318
Tresiba Flextouch U-200Insulin Degludec24$22,192
EliquisApixaban20$17,930
JanumetSitagliptin Phos/Metformin Hcl20$17,542
MounjaroTirzepatide13$11,798
FarxigaDapagliflozin Propanediol12$9,063
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,181
Janumet XrSitagliptin Phos/Metformin Hcl13$8,069
Novolog FlexpenInsulin Aspart29$7,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$539$108,18182 claims
MerckJanuvia, Janumet, Janumet Xr$184$70,18294 claims
GSKTrelegy Ellipta$24$55,07176 claims
Lilly USA, LLCTrulicity, Mounjaro$123$54,28052 claims
Boehringer IngelheimJardiance$152$47,44546 claims
Viiv Healthcare CompanyTivicay$101$33,01917 claims
AstraZenecaFarxiga$83$9,06312 claims
AbbVieSynthroid$49$36917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →